Chronos Archive seal

Review checklist: Richard Roundtree (HR-ML015)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the upfront surgery for cN1 disease, the chemotherapy choice, and the open question of post-mastectomy radiation.
provenance reviewnot_startedRecent-death rule: only what Roundtree said publicly (a 2000 PEOPLE interview as republished, a 2019 television interview) and the facts in his obituaries are used. The single versus double mastectomy conflict is recorded and not resolved. The physicians named in the PEOPLE article are not named in the record.
safe messaging reviewnot_startedBreast cancer in a man is described plainly; his embarrassment is recorded as his own public account and answered with information and support, never as a framing of the diagnosis; no behavioral-health diagnosis; the pancreatic cancer and death are recorded as history only.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Roundtree died in 2023. The case uses only what he made public himself (his 2000 PEOPLE interview as quoted in 2023, and a 2019 television interview), the facts in his obituaries, and his manager’s public statement on the cause of death. No physician of his made a public statement that was found. The PEOPLE article names his physician and his surgeon; neither is named in the record. No medical records, accounts by relatives, or speculation about undisclosed conditions are used. His tumor size, grade, receptor status, node count, stage, examination findings, results, germline testing, chemotherapy regimen, and preventive care are synthetic. The recent-death review rule applies.
  2. Men get breast cancer. The record says so plainly. It treats a new lump in a man as needing a prompt work-up whatever his earlier history. His own public words (that he “chalked it up” to adolescent gynecomastia, that he felt “embarrassment,” that he kept treatment secret to keep working, and that men “sweep it under the rug”) frame the teaching on stigma and delay. The record answers them with information, confidentiality, and peer support, and never frames the diagnosis itself as embarrassing or unmanly.
  3. Single or double mastectomy. Sources conflict. His own account in PEOPLE describes a modified radical mastectomy of the left breast. The Associated Press obituary and the encyclopedia article (citing a 2001 USA Today interview that was not read) say a double mastectomy. The conflict is recorded as claim CLM-0006 (certainty disputed) and is not resolved. The history does not take a side, and neither does the synthetic record. The operation is coded as mastectomy with axillary clearance for the left-sided cancer, and the pathology describes the left breast only. The consultant states that removal of the other breast is not needed for cancer control and is his choice. Later examination findings describe the chest without saying whether the right breast remains. No acquired-absence code is used.
  4. Index age and dates. He found the lump at the end of September 1993, at 51. The synthetic date of birth is July 9, 1975 (shift 33 years). The index visit on September 29, 2026 maps to September 29, 1993. Imaging and biopsy on September 30, the diagnosis visit and surgical consultation on October 5, surgery on October 7, the two-week review on October 20, the echocardiogram on October 23, and the preventive visit on October 27, 2026 map to the same days of 1993. This follows his account: diagnosis given in person four or five days after the doctor visit, and surgery a day or two later. The six months of chemotherapy he described begin after the episode ends and are recorded only as a plan. Past medical history holds only the gynecomastia at 13.
  5. Delay. The public accounts show that he saw his doctor within days, so the record does not invent a long delay. The teaching on delay rests on his own statements that he first attributed the lump to gynecomastia and felt embarrassment, and on his later account of secrecy. The Costa Rica location in the 2019 interview, and the week before he returned home, are recorded in the claims and are not used in the synthetic notes.
  6. Synthetic clinical picture. Everything clinical is synthetic and typical of breast cancer in men: a retroareolar, strongly hormone receptor-positive, HER2-negative invasive ductal carcinoma. It is grade 3 and 1.6 cm, with 2 of 15 nodes involved (pT1c pN1a, stage IIA). The grade and the two nodes make the chemotherapy he described a standard choice, and make a radiation oncology review after chemotherapy appropriate. The regimen (doxorubicin and cyclophosphamide, then weekly paclitaxel, about six months) is synthetic and matches only the duration he gave. Other results are normal or mild (PHQ-9 5 and 6, normal echocardiogram, normal blood tests), so that nothing reads as a claim about his undisclosed health. No sensitive-content claim was needed.
  7. Germline result. Germline testing is sent at diagnosis, as the ASCO guideline calls for in every man with breast cancer. The result is deliberately left pending at the end of the episode. Any result, positive or negative, would read as a claim about his genetics, and about a possible link to the pancreatic cancer that caused his death, which no source makes.
  8. Pancreatic cancer. His death from pancreatic cancer in 2023 is recorded as history only. It is not linked to the breast cancer, and the record does not mention it in the synthetic episode.
  9. Relatives. No relative is named or given any statement or health fact. The record has no family history entries. The advance care planning names an unnamed agent.
  10. Preventive visit. A periodic adult preventive visit (age 51, so `preventive_adult`) was added on October 27, 2026 (true frame October 27, 1993), timed before chemotherapy so that vaccines, hepatitis B screening, and a dental check come first. No sick visit was added: under the recent-death rule the case adds no synthetic illness episode. Judgment calls: (1) the never-smoker status and two or three drinks a week are synthetic; no fetched source covers them; (2) hepatitis B, hepatitis C, and HIV results are left for oncology and are not recorded; (3) zoster vaccination and colorectal screening are recorded as due after chemotherapy; (4) advance care planning records only general priorities, including his privacy, with no treatment preference.
  11. Focused visits. The two chronic-care follow-ups (the diagnosis visit six days after presentation and the review two weeks after surgery) are documented as focused visits on the ASCO male breast cancer guideline, the NCCN breast guideline, and the CMID breast cancer monograph. Each lists every item those protocols call for at that point, with its interval and status. The diagnosis visit is the same day as the surgical oncology consultation. One protocol deviation is recorded instead of an invented result: the baseline arm circumference recommended before axillary surgery was not measured. It was measured at thirteen days, equal on both sides and before any swelling, with the right arm as the reference, so no harm is judged to have resulted. Staging scans and tamoxifen safety checks are recorded as not indicated yet, with the reason. The medical oncology plan and the echocardiogram result are reported in prose because other teams made and resulted them.
  12. Consultation. The breast surgical oncology referral and the consultation by Farah Siddiqui, MD (a fictional consultant), on the day of the diagnosis visit, are S. The consultant answers the five referral questions with what the record shows happened afterwards: clinical stage IIA with no staging scans, surgery first with a left mastectomy and level I and II axillary dissection two days later (the other side left to his choice), germline testing sent without delaying surgery, a baseline arm measurement (missed, as recorded), drain and shoulder care, and medical oncology after the pathology, with a radiation oncology review if two or more nodes were involved. Her examination agrees with Dr. Carrington’s same-day note.
  13. Not used. His physicians’ names, accounts by relatives, the details of his later checkups, and his later life beyond the 2000 disclosure and the 2019 interview are not used. His height is not recorded in a fetched source; the 188 cm in the record is synthetic.
  14. Presenting concern. The intake documents list the presenting concern (PRB-003) rather than the breast cancer, which is recorded from the biopsy-results visit. The presenting-concern problem is synthetic (S); it is resolved, superseded by the diagnosis, from that visit on.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-10-05
Progress note 02 (C-CDA)
Baseline arm circumference before axillary surgeryOnce, before axillary surgeryNot measured today, a deviation from the protocol; the visit was taken up with the diagnosis and the plan. To be addressed after surgery
2026-10-20
Progress note 03 (C-CDA)
Baseline arm circumference missed before surgeryOnce, before axillary surgeryNot measured before the operation, a deviation from the protocol. Measured today at thirteen days, before any swelling, and equal on both sides; the right arm serves as the reference. No harm is evident, and future measurements will be compared with today's

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-10-05
Progress note 02 (C-CDA)
LaboratoryGermline multigene panel testingOrderedSent today; the result is not needed before surgery
2026-10-20
Progress note 03 (C-CDA)
ImagingEchocardiogram with ejection fraction before anthracyclineOrderedBooked this week
2026-10-20
Progress note 03 (C-CDA)
LaboratoryGermline multigene panel testingOrderedSent fifteen days ago; result not yet back
2026-10-27
Progress note 04 (C-CDA)
PreventionHepatitis B screening and vaccinationOrderedTriple panel drawn today, as recommended for all adults and before chemotherapy; vaccination if not immune
2026-10-27
Progress note 04 (C-CDA)
PreventionHepatitis C and HIV screeningOrderedOne-time screening recommended for all adults; no prior result; drawn with his consent today
2026-10-27
Progress note 04 (C-CDA)
PreventionDental examinationReferredNo dental visit in the past year; a check before chemotherapy is advised; booked this week

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

None.